{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:30:11Z","timestamp":1755221411076,"version":"3.43.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,8]]},"DOI":"10.7759\/cureus.89630","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T17:17:24Z","timestamp":1754673444000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the Oncologic and Safety Outcomes of High-Dose Palliative Radiation Treatment with 30 Grays in Five Fractions"],"prefix":"10.7759","author":[{"given":"Jim (Zhang Hao)","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma M","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee Suk","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina Wanting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronan","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00196-0","article-title":"Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial","volume":"22","author":"Sahgal A","year":"2021","unstructured":"Sahgal A, Myrehaug SD, Siva S, et al.. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol. 2021, 22:1023-33. 10.1016\/S1470-2045(21)00196-0","journal-title":"Lancet Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/15330338231164537","article-title":"Palliative radiotherapy for symptomatic locally advanced breast cancer","volume":"22","author":"Hoeltgen L","year":"2023","unstructured":"Hoeltgen L, Meixner E, Hoegen P, et al.. Palliative radiotherapy for symptomatic locally advanced breast cancer. Technol Cancer Res Treat. 2023, 22:1-8. 10.1177\/15330338231164537","journal-title":"Technol Cancer Res Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4859-7","article-title":"Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5","volume":"18","author":"Olson R","year":"2018","unstructured":"Olson R, Liu M, Bergman A, et al.. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer. 2018, 18:954. 10.1186\/s12885-018-4859-7","journal-title":"BMC Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma DA","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020, 38:2830-8. 10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5351","article-title":"Stereotactic ablative radiotherapy for the management of spinal metastases: a review","volume":"6","author":"Glicksman RM","year":"2020","unstructured":"Glicksman RM, Tjong MC, Neves-Junior WF, et al.. Stereotactic ablative radiotherapy for the management of spinal metastases: a review. JAMA Oncol. 2020, 6:567-77. 10.1001\/jamaoncol.2019.5351","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.7664","article-title":"Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus (PROACTIVE): a phase 3 randomized clinical trial","volume":"8","author":"Louie AV","year":"2022","unstructured":"Louie AV, Granton PV, Fairchild A, et al.. Palliative radiation for advanced central lung tumors with intentional avoidance of the esophagus (PROACTIVE): a phase 3 randomized clinical trial. JAMA Oncol. 2022, 8:562-8. 10.1001\/jamaoncol.2021.7664","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2018.02.028","article-title":"Cancer Trials Ireland (ICORG) 06-34: a multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer","volume":"127","author":"McDermott RL","year":"2018","unstructured":"McDermott RL, Armstrong JG, Thirion P, et al.. Cancer Trials Ireland (ICORG) 06-34: a multi-centre clinical trial using three-dimensional conformal radiation therapy to reduce the toxicity of palliative radiation for lung cancer. Radiother Oncol. 2018, 127:253-8. 10.1016\/j.radonc.2018.02.028","journal-title":"Radiother Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14886","article-title":"Prostate-specific membrane antigen-positron emission tomography\/computed tomography (PSMA-PET\/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature","volume":"124","author":"Ong WL","year":"2019","unstructured":"Ong WL, Koh TL, Lim Joon D, et al.. Prostate-specific membrane antigen-positron emission tomography\/computed tomography (PSMA-PET\/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature. BJU Int. 2019, 124:19-30. 10.1111\/bju.14886","journal-title":"BJU Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2022.02.021","article-title":"Hypofractionation in hepatocellular carcinoma - the effect of fractionation size","volume":"34","author":"Lewis S","year":"2022","unstructured":"Lewis S, Barry A, Hawkins MA. Hypofractionation in hepatocellular carcinoma - the effect of fractionation size. Clin Oncol (R Coll Radiol). 2022, 34:e195-209. 10.1016\/j.clon.2022.02.021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noq005","article-title":"Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases","volume":"12","author":"McPherson CM","year":"2010","unstructured":"McPherson CM, Suki D, Feiz-Erfan I, Mahajan A, Chang E, Sawaya R, Lang FF. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro Oncol. 2010, 12:711-9. 10.1093\/neuonc\/noq005","journal-title":"Neuro Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0247-2","article-title":"Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers","volume":"17","author":"Buckley AM","year":"2020","unstructured":"Buckley AM, Lynam-Lennon N, O'Neill H, O'Sullivan J. Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nat Rev Gastroenterol Hepatol. 2020, 17:298-313. 10.1038\/s41575-019-0247-2","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.14338\/IJPT-D-20-00076","article-title":"The role of particle therapy in adenoid cystic carcinoma and mucosal melanoma of the head and neck","volume":"8","author":"Ebner DK","year":"2021","unstructured":"Ebner DK, Malouff TD, Frank SJ, Koto M. The role of particle therapy in adenoid cystic carcinoma and mucosal melanoma of the head and neck. Int J Part Ther. 2021, 8:273-84. 10.14338\/IJPT-D-20-00076","journal-title":"Int J Part Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.12.014","article-title":"Efficacy and safety of reirradiation with stereotactic body radiation therapy for locally recurrent pancreatic adenocarcinoma","volume":"34","author":"Reddy AV","year":"2022","unstructured":"Reddy AV, Hill CS, Sehgal S, et al.. Efficacy and safety of reirradiation with stereotactic body radiation therapy for locally recurrent pancreatic adenocarcinoma. Clin Oncol (R Coll Radiol). 2022, 34:386-94. 10.1016\/j.clon.2021.12.014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-018-9922-x","article-title":"Locoregional control and survival after lymph node SBRT in oligometastatic disease","volume":"35","author":"Loi M","year":"2018","unstructured":"Loi M, Frelinghuysen M, Klass ND, et al.. Locoregional control and survival after lymph node SBRT in oligometastatic disease. Clin Exp Metastasis. 2018, 35:625-33. 10.1007\/s10585-018-9922-x","journal-title":"Clin Exp Metastasis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.033","article-title":"Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trial","volume":"114","author":"Baker S","year":"2022","unstructured":"Baker S, Jiang W, Mou B, et al.. Progression-free survival and local control after SABR for up to 5 oligometastases: an analysis from the population-based phase 2 SABR-5 trial. Int J Radiat Oncol Biol Phys. 2022, 114:617-26. 10.1016\/j.ijrobp.2022.05.033","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2021.02.007","article-title":"Palliative radiotherapy for advanced cancers: indications and outcomes","volume":"30","author":"Williams GR","year":"2021","unstructured":"Williams GR, Manjunath SH, Butala AA, Jones JA. Palliative radiotherapy for advanced cancers: indications and outcomes. Surg Oncol Clin N Am. 2021, 30:563-80. 10.1016\/j.soc.2021.02.007","journal-title":"Surg Oncol Clin N Am"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2022.05.043","article-title":"Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy","volume":"114","author":"Zeng KL","year":"2022","unstructured":"Zeng KL, Myrehaug S, Soliman H, et al.. Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2022, 114:293-300. 10.1016\/j.ijrobp.2022.05.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2147\/HP.S93413","article-title":"The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy","volume":"3","author":"Muz B","year":"2015","unstructured":"Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015, 3:83-92. 10.2147\/HP.S93413","journal-title":"Hypoxia (Auckl)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1533034616650778","article-title":"Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study","volume":"16","author":"Comito T","year":"2017","unstructured":"Comito T, Cozzi L, Clerici E, et al.. Can stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study. Technol Cancer Res Treat. 2017, 16:295-301. 10.1177\/1533034616650778","journal-title":"Technol Cancer Res Treat"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.08.056","article-title":"Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study","volume":"67","author":"Fossati N","year":"2015","unstructured":"Fossati N, Trinh QD, Sammon J, et al.. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. Eur Urol. 2015, 67:3-6. 10.1016\/j.eururo.2014.08.056","journal-title":"Eur Urol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker CC","year":"2018","unstructured":"Parker CC, James ND, Brawley CD, et al.. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet. 2018, 392:2353-66. 10.1016\/S0140-6736(18)32486-3","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma DA","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, et al.. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019, 393:2051-8. 10.1016\/S0140-6736(18)32487-5","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4394","article-title":"Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial","volume":"8","author":"Olson R","year":"2022","unstructured":"Olson R, Jiang W, Liu M, et al.. Treatment with stereotactic ablative radiotherapy for up to 5 oligometastases in patients with cancer: primary toxic effect results of the nonrandomized phase 2 SABR-5 clinical trial. JAMA Oncol. 2022, 8:1644-50. 10.1001\/jamaoncol.2022.4394","journal-title":"JAMA Oncol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.024","article-title":"Palliative radiation therapy for head and neck cancers","volume":"105","author":"Grewal AS","year":"2019","unstructured":"Grewal AS, Jones J, Lin A. Palliative radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2019, 105:254-66. 10.1016\/j.ijrobp.2019.05.024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2014.09.013","article-title":"Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer","volume":"27","author":"White R","year":"2015","unstructured":"White R, Khor R, Bressel M, et al.. Efficacy of high-dose palliative radiotherapy for localised, castration-resistant prostate cancer. Clin Oncol (R Coll Radiol). 2015, 27:16-21. 10.1016\/j.clon.2014.09.013","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00215","article-title":"Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries","volume":"8","author":"Kraus RD","year":"2022","unstructured":"Kraus RD, Weil CR, Abdel-Wahab M. Benefits of adopting hypofractionated radiotherapy as a standard of care in low-and middle-income countries. JCO Glob Oncol. 2022, 8:e2200215. 10.1200\/GO.22.00215","journal-title":"JCO Glob Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2024.08.001","article-title":"Safe hypofractionation amid diverse technologies: using teamwork to manage the complexity","volume":"34","author":"Lin MH","year":"2024","unstructured":"Lin MH, Arbab M, Pompos A, Wilcox L, Radpour S, Desai K, Timmerman R. Safe hypofractionation amid diverse technologies: using teamwork to manage the complexity. Semin Radiat Oncol. 2024, 34:395-401. 10.1016\/j.semradonc.2024.08.001","journal-title":"Semin Radiat Oncol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00148-7","article-title":"Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation","volume":"25","author":"Lichter KE","year":"2024","unstructured":"Lichter KE, Charbonneau K, Lewy JR, et al.. Quantification of the environmental impact of radiotherapy and associated secondary human health effects: a multi-institutional retrospective analysis and simulation. Lancet Oncol. 2024, 25:790-801. 10.1016\/S1470-2045(24)00148-7","journal-title":"Lancet Oncol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.07.1610","article-title":"Climate-smart oncology: can hypofractionation lighten radiotherapy\u2019s environmental load?","volume":"120","author":"Asaro A","year":"2024","unstructured":"Asaro A, Charbonneau K, Anand C, et al.. Climate-smart oncology: can hypofractionation lighten radiotherapy\u2019s environmental load?. Int J Radiat Oncol Biol Phys. 2024, 120:732. 10.1016\/j.ijrobp.2024.07.1610","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/391851-evaluating-the-oncologic-and-safety-outcomes-of-high-dose-palliative-radiation-treatment-with-30-grays-in-five-fractions","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T17:17:25Z","timestamp":1754673445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/391851-evaluating-the-oncologic-and-safety-outcomes-of-high-dose-palliative-radiation-treatment-with-30-grays-in-five-fractions"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.89630","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}